Skip to main content
Premium Trial:

Request an Annual Quote

Renalytix: Howard Doran

Renalytix has appointed Howard Doran a chief business officer, effective Sept. 1. He has more than 30 years of general management, strategic planning, and marketing and sales experience in the diagnostics and pharmaceutical industries. Doran was previously president and CEO of LipoScience until that firm was acquired by Labcorp in 2014. Before that, he was president and chief commercial officer of IVD firm Constitution Medical, which was acquired by Roche in 2013. Prior to that, Doran was president of Hologic's Global Diagnostics business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.